Update on cognitive decline and dementia in elderly patients with diabetes.
Identifieur interne : 001239 ( Main/Exploration ); précédent : 001238; suivant : 001240Update on cognitive decline and dementia in elderly patients with diabetes.
Auteurs : L. Bordier [France] ; J. Doucet [France] ; J. Boudet [France] ; B. Bauduceau [France]Source :
- Diabetes & metabolism [ 1878-1780 ] ; 2014.
Descripteurs français
- KwdFr :
- Adhésion au traitement médicamenteux (psychologie), Angiopathies diabétiques (complications), Angiopathies diabétiques (prévention et contrôle), Angiopathies intracrâniennes (complications), Angiopathies intracrâniennes (prévention et contrôle), Angiopathies intracrâniennes (étiologie), Autosoins (psychologie), Diabète de type 2 (complications), Diabète de type 2 (psychologie), Diabète de type 2 (sang), Diabète de type 2 (traitement médicamenteux), Démence (induit chimiquement), Démence (étiologie), Dépression (complications), Dépression (étiologie), Facteurs de risque (MeSH), Glycémie (métabolisme), Humains (MeSH), Hypoglycémiants (administration et posologie), Hypoglycémiants (effets indésirables), Hypoglycémie (complications), Hypoglycémie (induit chimiquement), Hémoglobine A glycosylée (métabolisme), Insuline (administration et posologie), Insuline (effets indésirables), Prévalence (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Troubles de la cognition (induit chimiquement), Troubles de la cognition (étiologie), Éducation du patient comme sujet (MeSH), Études longitudinales (MeSH).
- MESH :
- administration et posologie : Hypoglycémiants, Insuline.
- effets indésirables : Angiopathies diabétiques, Angiopathies intracrâniennes, Diabète de type 2, Dépression, Hypoglycémiants, Hypoglycémie, Insuline.
- induit chimiquement : Démence, Hypoglycémie, Troubles de la cognition.
- métabolisme : Glycémie, Hémoglobine A glycosylée.
- prévention et contrôle : Angiopathies diabétiques, Angiopathies intracrâniennes.
- psychologie : Adhésion au traitement médicamenteux, Autosoins, Diabète de type 2.
- sang : Diabète de type 2.
- traitement médicamenteux : Diabète de type 2.
- étiologie : Angiopathies intracrâniennes, Démence, Dépression, Troubles de la cognition.
- Facteurs de risque, Humains, Prévalence, Sujet âgé, Sujet âgé de 80 ans ou plus, Éducation du patient comme sujet, Études longitudinales.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Blood Glucose (metabolism), Cerebrovascular Disorders (complications), Cerebrovascular Disorders (etiology), Cerebrovascular Disorders (prevention & control), Cognition Disorders (chemically induced), Cognition Disorders (etiology), Dementia (chemically induced), Dementia (etiology), Depression (complications), Depression (etiology), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (drug therapy), Diabetes Mellitus, Type 2 (psychology), Diabetic Angiopathies (complications), Diabetic Angiopathies (prevention & control), Glycated Hemoglobin A (metabolism), Humans (MeSH), Hypoglycemia (chemically induced), Hypoglycemia (complications), Hypoglycemic Agents (administration & dosage), Hypoglycemic Agents (adverse effects), Insulin (administration & dosage), Insulin (adverse effects), Longitudinal Studies (MeSH), Medication Adherence (psychology), Patient Education as Topic (MeSH), Prevalence (MeSH), Risk Factors (MeSH), Self Care (psychology).
- MESH :
- chemical , administration & dosage : Hypoglycemic Agents, Insulin.
- chemical , adverse effects : Hypoglycemic Agents, Insulin.
- chemical , metabolism : Blood Glucose, Glycated Hemoglobin A.
- blood : Diabetes Mellitus, Type 2.
- chemically induced : Cognition Disorders, Dementia, Hypoglycemia.
- complications : Cerebrovascular Disorders, Depression, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Hypoglycemia.
- drug therapy : Diabetes Mellitus, Type 2.
- etiology : Cerebrovascular Disorders, Cognition Disorders, Dementia, Depression.
- prevention & control : Cerebrovascular Disorders, Diabetic Angiopathies.
- psychology : Diabetes Mellitus, Type 2, Medication Adherence, Self Care.
- Aged, Aged, 80 and over, Humans, Longitudinal Studies, Patient Education as Topic, Prevalence, Risk Factors.
Abstract
AIM
This article is an update of the relationship between type 2 diabetes (T2D), cognitive dysfunction and dementia in older people.
METHODS AND RESULTS
The number of older patients consulting for diabetes who also exhibit cognitive difficulties is consistently growing because of the increased longevity of the population as a whole and, according to a number of studies, the increased risk of cognitive impairment and dementia in older diabetic patients. Many studies have demonstrated a link between poor glucose control and deteriorated cognitive function in diabetic patients. A history of severe hypoglycaemic episodes has also been associated with a greater risk of late-in-life cognitive deficits and dementia in patients with T2D. Several processes are thought to promote cognitive decline and dementia in diabetics. Based on both clinical and non-clinical findings, the factors most likely to alter brain function and structure are cerebrovascular complications of diabetes, alterations in glucose and insulin, and recurrent hypoglycaemia. Together with other diabetes complications, cognitive deficits contribute to functional impairment, increased frequency of depression-related symptoms, greater incidence of recurrent hypoglycaemia, poorer adherence to treatment and, finally, poorer prognosis, as evidenced by recent longitudinal studies.
CONCLUSION
Clinical guidelines have recently been devised for older diabetic patients, particularly those with cognitive deficits and a reduced capacity to self-manage. In the most vulnerable patients, specific treatment strategies have been proposed for glycaemic control to limit metabolic decompensation and avoid the risk of hypoglycaemia. Educational measures, provided mainly to maintain patient autonomy and avoid hospital admission, have also been adapted according to patients' cognitive and functional status.
DOI: 10.1016/j.diabet.2014.02.002
PubMed: 24703603
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on cognitive decline and dementia in elderly patients with diabetes.</title><author><name sortKey="Bordier, L" sort="Bordier, L" uniqKey="Bordier L" first="L" last="Bordier">L. Bordier</name><affiliation wicri:level="3"><nlm:affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France. Electronic address: lbordier@club-internet.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Saint-Mandé</settlement></placeName></affiliation></author><author><name sortKey="Doucet, J" sort="Doucet, J" uniqKey="Doucet J" first="J" last="Doucet">J. Doucet</name><affiliation wicri:level="3"><nlm:affiliation>Geriatric Therapy and Internal Medicine Department, hôpital Saint-Julien, CHU de Rouen, 76031 Rouen cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Geriatric Therapy and Internal Medicine Department, hôpital Saint-Julien, CHU de Rouen, 76031 Rouen cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Boudet, J" sort="Boudet, J" uniqKey="Boudet J" first="J" last="Boudet">J. Boudet</name><affiliation wicri:level="3"><nlm:affiliation>Medical Endocrinology Department, Lilly France, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Endocrinology Department, Lilly France, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Neuilly-sur-Seine</settlement></placeName></affiliation></author><author><name sortKey="Bauduceau, B" sort="Bauduceau, B" uniqKey="Bauduceau B" first="B" last="Bauduceau">B. Bauduceau</name><affiliation wicri:level="3"><nlm:affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Saint-Mandé</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24703603</idno><idno type="pmid">24703603</idno><idno type="doi">10.1016/j.diabet.2014.02.002</idno><idno type="wicri:Area/Main/Corpus">001271</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001271</idno><idno type="wicri:Area/Main/Curation">001271</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001271</idno><idno type="wicri:Area/Main/Exploration">001271</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Update on cognitive decline and dementia in elderly patients with diabetes.</title><author><name sortKey="Bordier, L" sort="Bordier, L" uniqKey="Bordier L" first="L" last="Bordier">L. Bordier</name><affiliation wicri:level="3"><nlm:affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France. Electronic address: lbordier@club-internet.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Saint-Mandé</settlement></placeName></affiliation></author><author><name sortKey="Doucet, J" sort="Doucet, J" uniqKey="Doucet J" first="J" last="Doucet">J. Doucet</name><affiliation wicri:level="3"><nlm:affiliation>Geriatric Therapy and Internal Medicine Department, hôpital Saint-Julien, CHU de Rouen, 76031 Rouen cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Geriatric Therapy and Internal Medicine Department, hôpital Saint-Julien, CHU de Rouen, 76031 Rouen cedex</wicri:regionArea><placeName><region type="region" nuts="2">Région Normandie</region><region type="old region" nuts="2">Haute-Normandie</region><settlement type="city">Rouen</settlement></placeName></affiliation></author><author><name sortKey="Boudet, J" sort="Boudet, J" uniqKey="Boudet J" first="J" last="Boudet">J. Boudet</name><affiliation wicri:level="3"><nlm:affiliation>Medical Endocrinology Department, Lilly France, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Endocrinology Department, Lilly France, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Neuilly-sur-Seine</settlement></placeName></affiliation></author><author><name sortKey="Bauduceau, B" sort="Bauduceau, B" uniqKey="Bauduceau B" first="B" last="Bauduceau">B. Bauduceau</name><affiliation wicri:level="3"><nlm:affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Saint-Mandé</settlement></placeName></affiliation></author></analytic><series><title level="j">Diabetes & metabolism</title><idno type="eISSN">1878-1780</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Blood Glucose (metabolism)</term><term>Cerebrovascular Disorders (complications)</term><term>Cerebrovascular Disorders (etiology)</term><term>Cerebrovascular Disorders (prevention & control)</term><term>Cognition Disorders (chemically induced)</term><term>Cognition Disorders (etiology)</term><term>Dementia (chemically induced)</term><term>Dementia (etiology)</term><term>Depression (complications)</term><term>Depression (etiology)</term><term>Diabetes Mellitus, Type 2 (blood)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Diabetes Mellitus, Type 2 (psychology)</term><term>Diabetic Angiopathies (complications)</term><term>Diabetic Angiopathies (prevention & control)</term><term>Glycated Hemoglobin A (metabolism)</term><term>Humans (MeSH)</term><term>Hypoglycemia (chemically induced)</term><term>Hypoglycemia (complications)</term><term>Hypoglycemic Agents (administration & dosage)</term><term>Hypoglycemic Agents (adverse effects)</term><term>Insulin (administration & dosage)</term><term>Insulin (adverse effects)</term><term>Longitudinal Studies (MeSH)</term><term>Medication Adherence (psychology)</term><term>Patient Education as Topic (MeSH)</term><term>Prevalence (MeSH)</term><term>Risk Factors (MeSH)</term><term>Self Care (psychology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion au traitement médicamenteux (psychologie)</term><term>Angiopathies diabétiques (complications)</term><term>Angiopathies diabétiques (prévention et contrôle)</term><term>Angiopathies intracrâniennes (complications)</term><term>Angiopathies intracrâniennes (prévention et contrôle)</term><term>Angiopathies intracrâniennes (étiologie)</term><term>Autosoins (psychologie)</term><term>Diabète de type 2 (complications)</term><term>Diabète de type 2 (psychologie)</term><term>Diabète de type 2 (sang)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Démence (induit chimiquement)</term><term>Démence (étiologie)</term><term>Dépression (complications)</term><term>Dépression (étiologie)</term><term>Facteurs de risque (MeSH)</term><term>Glycémie (métabolisme)</term><term>Humains (MeSH)</term><term>Hypoglycémiants (administration et posologie)</term><term>Hypoglycémiants (effets indésirables)</term><term>Hypoglycémie (complications)</term><term>Hypoglycémie (induit chimiquement)</term><term>Hémoglobine A glycosylée (métabolisme)</term><term>Insuline (administration et posologie)</term><term>Insuline (effets indésirables)</term><term>Prévalence (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Troubles de la cognition (induit chimiquement)</term><term>Troubles de la cognition (étiologie)</term><term>Éducation du patient comme sujet (MeSH)</term><term>Études longitudinales (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hypoglycemic Agents</term><term>Insulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hypoglycemic Agents</term><term>Insulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Blood Glucose</term><term>Glycated Hemoglobin A</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hypoglycémiants</term><term>Insuline</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term><term>Dementia</term><term>Hypoglycemia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Depression</term><term>Diabetes Mellitus, Type 2</term><term>Diabetic Angiopathies</term><term>Hypoglycemia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Angiopathies diabétiques</term><term>Angiopathies intracrâniennes</term><term>Diabète de type 2</term><term>Dépression</term><term>Hypoglycémiants</term><term>Hypoglycémie</term><term>Insuline</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Cognition Disorders</term><term>Dementia</term><term>Depression</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Démence</term><term>Hypoglycémie</term><term>Troubles de la cognition</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycémie</term><term>Hémoglobine A glycosylée</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Diabetic Angiopathies</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Angiopathies diabétiques</term><term>Angiopathies intracrâniennes</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Adhésion au traitement médicamenteux</term><term>Autosoins</term><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term><term>Medication Adherence</term><term>Self Care</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Angiopathies intracrâniennes</term><term>Démence</term><term>Dépression</term><term>Troubles de la cognition</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Longitudinal Studies</term><term>Patient Education as Topic</term><term>Prevalence</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Humains</term><term>Prévalence</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Éducation du patient comme sujet</term><term>Études longitudinales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIM</b></p><p>This article is an update of the relationship between type 2 diabetes (T2D), cognitive dysfunction and dementia in older people.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS AND RESULTS</b></p><p>The number of older patients consulting for diabetes who also exhibit cognitive difficulties is consistently growing because of the increased longevity of the population as a whole and, according to a number of studies, the increased risk of cognitive impairment and dementia in older diabetic patients. Many studies have demonstrated a link between poor glucose control and deteriorated cognitive function in diabetic patients. A history of severe hypoglycaemic episodes has also been associated with a greater risk of late-in-life cognitive deficits and dementia in patients with T2D. Several processes are thought to promote cognitive decline and dementia in diabetics. Based on both clinical and non-clinical findings, the factors most likely to alter brain function and structure are cerebrovascular complications of diabetes, alterations in glucose and insulin, and recurrent hypoglycaemia. Together with other diabetes complications, cognitive deficits contribute to functional impairment, increased frequency of depression-related symptoms, greater incidence of recurrent hypoglycaemia, poorer adherence to treatment and, finally, poorer prognosis, as evidenced by recent longitudinal studies.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Clinical guidelines have recently been devised for older diabetic patients, particularly those with cognitive deficits and a reduced capacity to self-manage. In the most vulnerable patients, specific treatment strategies have been proposed for glycaemic control to limit metabolic decompensation and avoid the risk of hypoglycaemia. Educational measures, provided mainly to maintain patient autonomy and avoid hospital admission, have also been adapted according to patients' cognitive and functional status.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24703603</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1780</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Diabetes & metabolism</Title><ISOAbbreviation>Diabetes Metab</ISOAbbreviation></Journal><ArticleTitle>Update on cognitive decline and dementia in elderly patients with diabetes.</ArticleTitle><Pagination><MedlinePgn>331-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabet.2014.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1262-3636(14)00036-6</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">This article is an update of the relationship between type 2 diabetes (T2D), cognitive dysfunction and dementia in older people.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">The number of older patients consulting for diabetes who also exhibit cognitive difficulties is consistently growing because of the increased longevity of the population as a whole and, according to a number of studies, the increased risk of cognitive impairment and dementia in older diabetic patients. Many studies have demonstrated a link between poor glucose control and deteriorated cognitive function in diabetic patients. A history of severe hypoglycaemic episodes has also been associated with a greater risk of late-in-life cognitive deficits and dementia in patients with T2D. Several processes are thought to promote cognitive decline and dementia in diabetics. Based on both clinical and non-clinical findings, the factors most likely to alter brain function and structure are cerebrovascular complications of diabetes, alterations in glucose and insulin, and recurrent hypoglycaemia. Together with other diabetes complications, cognitive deficits contribute to functional impairment, increased frequency of depression-related symptoms, greater incidence of recurrent hypoglycaemia, poorer adherence to treatment and, finally, poorer prognosis, as evidenced by recent longitudinal studies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Clinical guidelines have recently been devised for older diabetic patients, particularly those with cognitive deficits and a reduced capacity to self-manage. In the most vulnerable patients, specific treatment strategies have been proposed for glycaemic control to limit metabolic decompensation and avoid the risk of hypoglycaemia. Educational measures, provided mainly to maintain patient autonomy and avoid hospital admission, have also been adapted according to patients' cognitive and functional status.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bordier</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France. Electronic address: lbordier@club-internet.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doucet</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Geriatric Therapy and Internal Medicine Department, hôpital Saint-Julien, CHU de Rouen, 76031 Rouen cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudet</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Endocrinology Department, Lilly France, boulevard Vital-Bouhot, 92521 Neuilly-sur-Seine cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauduceau</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Endocrinology Department, hôpital Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Diabetes Metab</MedlineTA><NlmUniqueID>9607599</NlmUniqueID><ISSNLinking>1262-3636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012648" MajorTopicYN="Y">Self Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Elderly patient</Keyword><Keyword MajorTopicYN="N">Hypoglycaemia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24703603</ArticleId><ArticleId IdType="pii">S1262-3636(14)00036-6</ArticleId><ArticleId IdType="doi">10.1016/j.diabet.2014.02.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Haute-Normandie</li><li>Région Normandie</li><li>Île-de-France</li></region><settlement><li>Neuilly-sur-Seine</li><li>Rouen</li><li>Saint-Mandé</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Bordier, L" sort="Bordier, L" uniqKey="Bordier L" first="L" last="Bordier">L. Bordier</name></region><name sortKey="Bauduceau, B" sort="Bauduceau, B" uniqKey="Bauduceau B" first="B" last="Bauduceau">B. Bauduceau</name><name sortKey="Boudet, J" sort="Boudet, J" uniqKey="Boudet J" first="J" last="Boudet">J. Boudet</name><name sortKey="Doucet, J" sort="Doucet, J" uniqKey="Doucet J" first="J" last="Doucet">J. Doucet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001239 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001239 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24703603
|texte= Update on cognitive decline and dementia in elderly patients with diabetes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24703603" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |